Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial

By Ali Ahmed, M. Rich, J. Fleg, M. Zile, James B. Young, D. Kitzman, T. Love, W. Aronow, K. Adams, M. Gheorghiade. Circulation, 2006

621 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Complementary and alternative medicine

View Paper: https://www.semanticscholar.org/paper/95138485a73481a7dd1fed83576740a21d6ac050

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Ramachandran S. Vasan
2. M. Gheorghiade
3. Barry A. Borlaug

Citations in the corpus

• 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “79).(544,545) There have been no head-to-head RCTs of digoxin in AF patients.”
• Acute heart failure syndromes (2009, background): “It is possible that a signifcant number of morbid events in the AHFS/PSF poplation are related to coexisting cardiac or noncardiac omorbidities, such as CAD, hypertension, atrial fibrilation, renal insufficiency, or stroke (34,35).”
• Epidemiology and clinical course of heart failure with preserved ejection fraction (2011, background): “Clinical trial 28 72 Ahmed et al.(56) Clinical trial 30 70 Massie et al.”
• Heart failure with preserved ejection fraction. (2006, background): “Of note, the majority of HFPEF patients in this trial had ischemic aetiology (56%), and most of hospitalizations were related to unstable angina((33)).”